Keywords
Alzheimer Disease ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

245 Search results.

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Diagnosis criteria Amyotrophic lateral sclerosis (ALS) (Diagnosekriterien Amyotrophe Lateralsklerose (ALS))

- 9/20/21 - 1 form, 12 itemgroups, 34 items, 1 language
Itemgroups: Administrative Data, Amyotrophic lateral sclerosis (ALS), Diagnostic criteria and motor subtypes, classical ALS, ALS exclusion criteria, Diagnosis facilitation, ALS occurrence, ALS (not impaired) without cognitive impairment, ALS (cognitive impaired), ALS (behaviourally impaired), ALS (cognitively and behaviourally impaired), ALS‐FTD, ALS (without cognitive impairment, genetic risk for FTD)
DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the Diagnosis criteria Amyotrophic lateral sclerosis (ALS) form. It has to be filled in if an ALS is diagnosed. Note: If there is a motor neuron disease, fill in the motor neuron disease assessment!

Eligibility Caregivers NCT00558402

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Meditation or Education for Alzheimer Caregivers; ODM derived from: https://clinicaltrials.gov/show/NCT00558402

Study of Alzheimer's Disease in Down Syndrome NCT02141971 - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented subjects between ages 40-50 years old, and four demented subjects 50-60 years old. ODM derived from: https://clinicaltrials.gov/show/NCT02141971

Eligibility Alzheimer Disease NCT00322036

- 9/20/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's; ODM derived from: https://clinicaltrials.gov/show/NCT00322036

Eligibility Alzheimer Disease NCT00253214

- 9/20/21 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation; ODM derived from: https://clinicaltrials.gov/show/NCT00253214

Eligibility Alzheimer Disease NCT00088673

- 9/20/21 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00088673

Eligibility Alzheimer Disease NCT00062569

- 9/20/21 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: Criteria
Bathing Persons With Alzheimer's Disease aT Home (The BATH Study); ODM derived from: https://clinicaltrials.gov/show/NCT00062569

Eligibility Alzheimer Disease NCT00979316

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00979316

Eligibility Alzheimer Disease NCT00908492

- 9/20/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Supporting Caregivers of Persons With Dementia: A Pilot Study; ODM derived from: https://clinicaltrials.gov/show/NCT00908492

GSK AVA100193 Rosiglitazone in Alzheimer´s Disease - Screening Visit - Screening Visit

- 9/20/21 - 1 form, 15 itemgroups, 90 items, 1 language
Itemgroups: Neuropsychological Tests, Demography, Alzheimers disease diagnosis and course, Vital Signs, Education History, Neurological Examination, Physical Examination, Pedal Edema, Tobacco use, Medical History, Concomitant Medication, Screening summary, Eligibility Inclusion criteria, Eligibility Exclusion criteria, Investigator Signature
A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease.

Eligibility Alzheimer Disease NCT00556660

- 9/20/21 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00556660

Eligibility Alzheimer Disease NCT00506415

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline; ODM derived from: https://clinicaltrials.gov/show/NCT00506415